IL2 and primary cutaneous T-cell non-Hodgkin lymphoma: IL-2 can be used as a single drug treatment for cancer therapies, or it can be combined with other chemotherapy; for example, IL-2 fused with Diphtheria toxin proteins showed promising results in phase III trials of cutaneous T cell lymphoma (CTCL) patients [144].